H Kennecke1, S Berry2, J Maroun3, P Kavan4, N Aucoin5, F Couture6, M Poulin-Costello7, B Gillesby7. 1. Virginia Mason Cancer Institute, Seattle, WA, U.S.A. 2. Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON. 3. Medical Oncology, Faculty of Medicine, University of Ottawa, Ottawa, ON. 4. Department of Oncology, Faculty of Medicine, McGill University, Montreal, QC. 5. Hôpital de la Cité-de-la-Santé, Laval, QC. 6. Centre hospitalier universitaire de Québec, Quebec City, QC. 7. Amgen Canada, Inc., Mississauga, ON.
Abstract
Background: Selection and sequencing of treatment regimens for individual patients with metastatic colorectal cancer (mcrc) is driven by maintaining reasonable quality of life and extending survival, as well as by access to and cost of therapies. The objectives of the present study were to describe, for patients with mcrc, attrition across lines of systemic therapy, patterns of therapy and their timing, and KRAS status. Methods: A retrospective chart review at 6 Canadian academic centres included sequential patients who were diagnosed with mcrc from 1 January 2009 onward and who initiated first-line systemic treatment for mcrc between 1 January and 31 December 2009. Death was included as a competing risk in the analysis. Results: The analysis included 200 patients who started first-line therapy. The proportions of patients who started second-, third-, and fourth-line systemic therapy were 70%, 30%, and 15% respectively. Chemotherapy plus bevacizumab was the most common first-line combination (66%). The most common first-line regimen was folfiri plus bevacizumab. KRAS testing was performed in 103 patients (52%), and 38 of 68 patients (56%, 19% overall) with confirmed KRAS wild-type tumours received an epidermal growth factor receptor inhibitor (egfri), which was more common in later lines. Most KRAS testing occurred after initiation of second-line therapy. Conclusions: In the modern treatment era, a high proportion of patients receive at least two lines of therapy for mcrc, but only 19% receive egfri therapy. Earlier KRAS testing and therapy with an egfri might allow a greater proportion of patients to access all 5 active treatment agents. 2019 Multimed Inc.
Background: Selection and sequencing of treatment regimens for individual patients with metastatic colorectal cancer (mcrc) is driven by maintaining reasonable quality of life and extending survival, as well as by access to and cost of therapies. The objectives of the present study were to describe, for patients with mcrc, attrition across lines of systemic therapy, patterns of therapy and their timing, and KRAS status. Methods: A retrospective chart review at 6 Canadian academic centres included sequential patients who were diagnosed with mcrc from 1 January 2009 onward and who initiated first-line systemic treatment for mcrc between 1 January and 31 December 2009. Death was included as a competing risk in the analysis. Results: The analysis included 200 patients who started first-line therapy. The proportions of patients who started second-, third-, and fourth-line systemic therapy were 70%, 30%, and 15% respectively. Chemotherapy plus bevacizumab was the most common first-line combination (66%). The most common first-line regimen was folfiri plus bevacizumab. KRAS testing was performed in 103 patients (52%), and 38 of 68 patients (56%, 19% overall) with confirmed KRAS wild-type tumours received an epidermal growth factor receptor inhibitor (egfri), which was more common in later lines. Most KRAS testing occurred after initiation of second-line therapy. Conclusions: In the modern treatment era, a high proportion of patients receive at least two lines of therapy for mcrc, but only 19% receive egfri therapy. Earlier KRAS testing and therapy with an egfri might allow a greater proportion of patients to access all 5 active treatment agents. 2019 Multimed Inc.
Authors: Matthew Chan; Kiara Hugh-Yeun; Gillian Gresham; Caroline H Speers; Hagen F Kennecke; Winson Y Cheung Journal: Clin Colorectal Cancer Date: 2016-08-30 Impact factor: 4.481
Authors: Thomas A Abrams; Gary Meyer; Deborah Schrag; Jeffrey A Meyerhardt; Julie Moloney; Charles S Fuchs Journal: J Natl Cancer Inst Date: 2014-02 Impact factor: 13.506
Authors: Eric Van Cutsem; Claus-Henning Köhne; Erika Hitre; Jerzy Zaluski; Chung-Rong Chang Chien; Anatoly Makhson; Geert D'Haens; Tamás Pintér; Robert Lim; György Bodoky; Jae Kyung Roh; Gunnar Folprecht; Paul Ruff; Christopher Stroh; Sabine Tejpar; Michael Schlichting; Johannes Nippgen; Philippe Rougier Journal: N Engl J Med Date: 2009-04-02 Impact factor: 91.245
Authors: James McLean; Young Soo Rho; Gayathri Kuruba; Aline Mamo; Marine Gilabert; Tomas Kavan; Lawrence Panasci; David Melnychuk; Gerald Batist; Petr Kavan Journal: Clin Colorectal Cancer Date: 2015-10-21 Impact factor: 4.481
Authors: N Boeckx; R Koukakis; K Op de Beeck; C Rolfo; G Van Camp; S Siena; J Tabernero; J-Y Douillard; T André; M Peeters Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976